OrbiMed reports 7.3% stake in Spruce Biosciences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
OrbiMed Advisors LLC and OrbiMed Capital LLC report institutional ownership in Spruce Biosciences, Inc. The filing states that OrbiMed Advisors beneficially owns 132,200 shares of Spruce’s common stock, representing 4.8% of the outstanding class, while OrbiMed Capital beneficially owns 67,800 shares, representing 2.5%.
OrbiMed Advisors has shared voting and dispositive power over 132,200 shares, and OrbiMed Capital has sole voting and dispositive power over 67,800 shares. The reporting persons hold 7.3% of Spruce’s common stock in the aggregate on behalf of other persons who are entitled to dividends and sale proceeds. Investment and voting power are exercised through a management committee, whose members disclaim beneficial ownership.
Key Figures
Key Terms
beneficial ownership financial
sole dispositive power financial
Schedule 13G regulatory
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Spruce Biosciences (SPRB) does OrbiMed Advisors LLC report owning?
What is OrbiMed’s aggregate ownership stake in Spruce Biosciences (SPRB)?
Who controls investment and voting decisions for OrbiMed’s Spruce Biosciences (SPRB) holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.